natgillin/translations-raw huggingface dataset:
The rodent of claim 1, wherein the rodent comprises a replacement of a genomic fragment of a rodent IL-4 gene at an endogenous rodent IL-4 locus with a genomic fragment of a human IL-4 gene to form a humanized IL-4 gene, wherein the genomic fragment of the rodent IL-4 gene comprises the ATG initiation codon of exon 1 through exon 4 of the rodent IL-4 gene, and the genomic fragment of the human IL-4 gene comprises the ATG initiation codon of exon 1 through exon 4 of the human IL-4 gene, and wherein expression of the humanized IL-4 gene is under control of rodent IL-4 regulatory elements at the endogenous rodent IL-4 locus. 
Glodavac u skladu s patentnim zahtjevom 1, naznačen time što glodavac sadrži zamjenu genomskog fragmenta gena za glodavački IL-4 na lokusu za endogeni glodavački IL-4 genomskim fragmentom gena za ljudski IL-4 kako bi se dobilo gen za humanizirani IL-4, gdje genomski fragment gena za glodavački IL-4 sadrži početni kodon ATG egzona 1 do egzona 4 gena za glodavački IL-4, a genomski fragment gena za ljudski 1I-4 sadrži početni kodon ATG egzona 1 do egzona 4 gena za ljudski IL-4, te gdje je eksprimiranje gena za humanizirani IL-4 pod kontrolom regulacijskih elemenata glodavačkog IL-4 na lokusu za endogeni glodavački IL-4.
The method of claim 6, further comprising including in the payment authorization text message from the mobile phone of the user a personal identification code unique to the user. 
Metoda prema zahtjevu 5, dalje sadržeći uključivanje u tekstualnoj poruci autorizacije plaćanja od strane mobilnog telefona korisnika (102) osobni identifikacijski kod jedinstven za korisnika (102).
The pharmaceutical composition of claim 1 wherein upon storage of the composition at 30° C. and 65% RH for a period of 6 months, the composition has a second peroxide value not greater than 10 meq/kg. 
Farmaceutski pripravak prema zahtjevu 1 naznačen time da nakon skladištenja pripravka na 30 "C i 65% RH kroz period od 6 mjeseci, EPA ima drugu peroksidnu vrijednost ne veću od 12 Meqg/kg, ili ne veću od 10 Meq/kg, ili ne veću od 6 Meq/kg.
A conjugate according to claims 3 to 5 wherein the cell binding agent has been modified by a modifying agent to improve the reactivity of the cell binding agent towards the linking group of the linker. 
Konjugat u skladu s patentnim zahtjevom 3 do 5, naznačen time što sredstvo za vezanje na stanicu se modificira modificirajućim sredstvom kako bi se povećala reaktivnost sredstva za vezanje na stanicu prema povezujućoj skupini spojnice.
In some embodiments, the pharmaceutical composition further comprises one or more agents selected from the group consisting of a-glucosidase inhibitor, aldose reductase inhibitor, biguanide, HMG-CoA reductase inhibitor, squalene synthesis inhibitor, fibrate, LDL catabolism enhancer, angiotensin converting enzyme inhibitor, insulin secretion enhancer and thiazolidinedione. 
HR P20060286 T3 čine inhibitori a-glukozidaze, inhibitor aldoza reduktaze, bigvanidi, inhibitori HMG-CoA reduktaze, inhibitor sinteze skvalena, fibrat, poboljšivači katabolizma LDL, inhibitori angiotenzin-konvertaza enzima, poboljšivači izlučivanja inzulina i tiazolidindion.
the SNP having a minor allele frequency of 0.4 or greater is a SNP set forth in Table 1. 
SNP koji ima manju frekvenciju alela od 0,4 ili više je SNP naveden u tablici 1.
Use of the dihydrochloride salt according to claim 1 or 2 for the preparation of a medicament for the treatment and/or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, more particularly for the treatment or prophylaxis of a cancer, particularly lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer, hepatocyte carcinoma, or breast cancer. 
Uporaba dihidrokloridne soli prema zahtjevu 1 ili 2 naznačena time da je za pripravu medikamenta za liječenje i/ili profilaksu bolesti, naročito hiper-proliferativnog poremećaja 1/ili poremećaja angiogeneze, te naročito za liječenje ili profilaksu raka, naročito raka pluća, osobito raka pluća ne-malih stanica, raka debelog crijeva, melanoma, raka gušterače, karcinoma hepatocita, 1li raka dojke.
an X-ray powder diffraction (XRPD) pattern that comprises peaks at 11.2, 12.9, 15.5, 17.8, 19.1, 20.0, 20.6, 20.7, 21.2 and 22.8 and 28.2 degrees 2θ (± 0.1 degrees 2θ), wherein said XRPD is made using CuKa1 radiation; and a Raman spectra that comprises peaks at 353, 688, and 825 cm-1; preferably 
modelom rendgenske difrakcije praha (XRPD) s vršnim točkama na 11,2, 12,9, 15,5, 17,8, 19,1, 20,0, 20,6, 20,7, 21,2 i 22,8 stupnjeva 2θ (± 0,1 stupanj 2θ), naznačen time, što je spomenuti XRPD dobiven primjenom CuKa1 zračenja; i Ramanovim spektrom s vršnim točkama na 353, 688 i 825 cm-1; poželjno
The filtering apparatus according to claim 3, wherein the emission device comprises injectors and ejectors that generate the countercurrent gas pulse flow at the one or more filters, which removes ash accumulated on the one or more filters. 
Uređaj za filtriranje (1) prema jednom ili više od prethodnih zahtjeva, naznačen time što navedena emisijska sredstva obuhvaćaju injektore (14, 24) i izbacivače (15, 25) koji stvaraju pulsni protok protustrujnog plina na tim filterima (13, 23), čime se uklanja pepeo nakupljen na filterima.
the reaction is carried out at a temperature from 100°C to 220°C 
reakcija se izvodi na temperaturi od 100 °C do 220 °C
The method of statement 1 wherein the drive signal having the first frequency and the drive signal having the second frequency do not overlap. 
Sustav u skladu sa zahtjevom 1, naznačen time, da su upravljačka sredstva nadalje podešena da prenose upravljački signal tako da se prva frekvencija i druga frekvencija ne preklapaju.
System for receiving digital signals comprising a QAM demodulator, characterized in that it implements the method according to claim3. 
Sustav za primanje digitalnih signala koji sadrži QAM demodulator, naznačen time, da je prilagođen za primjenu postupka u skladu s bilo kojim od patentnih zahtjeva 6 do 8.
The method of claim 1, comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:35 residues 1-378. 
Polipeptid iz bilo kojeg od patentnih zahtjeva 1-4, sadrži najmanje 85% identičnu aminokiselinskoj sekvenci u skladu sa SEK ID BR:1 ili SEK ID BR:35.
Figure 3b shows that the engraved design in the plate has been transferred into the ink patch with good resolution, which remains substantially unchanged by the filling of the engraving with a polymer. 
Slika 3b prikazuje kako je uzorak ugraviran na ploči prenesen u dobroj rezoluciji na otisak tinte, koja se bitno ne mijenja kada se gravura ispuni polimerom.
Inhibitory effects of compounds of the formula (I) against angiotensin II induced pressor response in rats 
HR P20120667 T1 PATENTNI ZAHTJEVI Postupak proizvodnje spoja formule (I):
is a hydrogen atom, C1-4 alkyl optionally substituted with one or more substituents Rf, C6-10 aryl optionally substituted with one or more substituents Rg, (C1-6 alkyl)carbonyl, C6-10 aryl)carbonyl, a group -CONR37R38 C3-7 cycloalkyl, or 5- to 8-membered heterocycloalkyl; and R5 is a hydrogen atom or C1-4 alkyl; 
je vodikov atom, C1-4 alkil po izboru supstituiran s jednim ili više supstituenata Rf, C6-10 aril po izboru supstituiran s jednim ili više supstituenata Rg, (C1-6 alkil)karbonil, (C6-10 aril)karbonil, skupinom -C(O)NR37R38, C3-7 cikloalkil, ili 5- do 8-člani heterocikloalkil; i je vodikov atom ili C1-4 alkil; i
Load: concentrated crude material (CCM) containing 0.50 mg/ml r-hIL-18BP (ELISA) and 32 mg/ml total protein (Bradford)—flow rate 1 ml/min. 
Punjenje: koncentrirani sirovi materijal (CCM) koji sadržava 0.50 mg/ml r-hIL-18BP (ELISA) i ukupno 32 mg/ml proteina (Bradford) - brzina protoka 1 ml/min.
A product for the biological control of phytopathogenic fungi and stimulating plant growth according to claim 4, containing, in addition to the bacterial cells, the supernatant of the culture. 
Proizvod za biološku kontrolu fitopatogenih gljivica i stimuliranje rasta biljaka temeljem jednog od zahtjeva 2 do 5, naznačen time što između ostalog sadrži, osim bakterijskih stanica, supernatant kulture sa organskom tvari 1 supstance sa antifungalnom aktivnošću.
Yet another embodiment is said compounds of the invention for use in a method of treating cells or tissues involved in a pathology characterized by dysfunctional neuronal cells caused by misregulation of the gene associated with the enzyme pantothene kinase. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen upotrebi kao medikament za liječenje stanica ili tkiva uključenih u patologiju, naznačen time što postoje disfunkcionalne živčane stanice zbog krive regulacije gena povezanog s enzimom pantotenat-kinazom.
The unbound and eluted fractions were collected and analysed by SDS-PAGE. 
Nevezane i eluirane frakcije su sakupljene i analizirane tehnikom SDS-PAGE.
More specifically, on the basis of the input data, an appropriate telegram TG1, TG2, TG3, TG4 is generated in known manner for each of the four beacons, and, from the four telegrams TG1, TG2, TG3, TG4, an overall telegram is formed comprising a number of groups of successive bits, each group comprising bits having corresponding locations in the various telegrams. 
Određenije, na osnovi ulaznih podataka, odgovarajući telegram TG1, TG2, TG3, TG4 se na poznati način generira za svaku od četiri balize i iz četiri telegrama TG1, TG2, TG3, TG4 se formira cjeloviti telegram koji sadrži odredeni broj grupa sukcesivnih bitova, a svaka grupa sadrži bitove koji imaju odgovarajuće lokacije u različitim telegramima.
The method of any of claims 1 to 11, wherein the 1st reactant is a compound of formula R2-C≡C-H II, wherein R2 is a substituent selected from the group consisting of C1-6-alkyl, C3-10-cycloalkyl, aryl, heteroaryl and aralkyl, and wherein each cycloalkyl, aryl, heteroaryl or aralkyl can carry one or more further substituents selected from the group consisting of C1-6-alkyl, C1-6-alkoxy and tri-C1-6-alkylsilyloxy. 
Postupak prema bilo kojem zahtjevu od 1 do 11, naznačen time, da je prvi reaktant spoj formule -C≡C-H II, gdje R2 je supstituent odabaran iz skupine koja se sastoji od C1-6-alkila, C3-10-cikloalkila, arila, heteroarila i aralkila, pri čemu svaki cikloalkil, aril, heteroaril ili aralkil može nositi jednog ili više daljnjih supstituenata odabranih iz skupine koja se sastoji od C1-6-alkila, C1-6-alkoksi i tri-C1-6-alkilsililoksi.
Figure 1: View of the locking nail. 
Datum podnošenja europske prijave patenta:
The method of claim 1 wherein the compound 1c is 3-chloro-4-(6-hydroxyquinolin-2-yl)benzoic acid. 
Spoj ili sol prema zahtjevu 6, naznačen/a time, da spoj je 3-kloro-4-(6-hidroksikinolin-2-il)benzoeva kiselina.
The wet cooling tower according to claim 1, wherein signal processor comprises a computer and optionally further comprising a display device in data signal communication with the computer. 
Mokri rashladni toranj prema zahtjevu 1, pri čemu kompjuter (300) dalje sadrži uređaj (302) u vidu ekrana za prikazivanje slike koji omogućava da korisnik ili operater vizualno nadzire signale koji izlaze iz senzora toplote, temperature, vibracija i strujanja zraka.
Method for producing a laminated product, for example a building panel, preferably a floor panel (P), wherein the method comprising the steps of: 
Postupak za proizvodnju laminiranog proizvoda, na primjer građevinske ploče, poželjno podne ploče (P), naznačen time što postupak obuhvaća sljedeće korake:
Use of the fungicidal composition according to claim 8 in the control of grape downy mildew, wheat rust, potato late blight, wheat powdery mildew, tomato grey mold or grape anthracnose. 
Primjena fungicidne kompozicije u skladu sa patentnim zahtjevom 8 u kontroli plamenjače (down mildew) grožđa, hrđe pšenice, kasne paleži krumpira, pepelnice pšenice, sive truleži rajčice ili antraknoze grožđa.
An activated cytotoxic T lymphocyte (CTL), produced by the method according to claim 9, that selectively recognises a cell which aberrantly expresses a polypeptide comprising an amino acid sequence given in claim 1. 
Aktivirani citotoksični T-limfocit (CTL), proizveden metodom u skladu s patentnim zahtjevom 9, koji selektivno prepoznaje stanicu koja abnormalno eksprimira polipeptid koji se sastoji od sekvence aminokiselina navedene u patentnom zahtjevu 1.
The crystalline succinate salt of Desfesoterodine of claim 6, wherein the crystalline form of Desfesoterodine succinate, designated as Form S1, is characterized by data selected from one or more of the following: an X-ray powder diffraction pattern having peaks at 7.4, 16.8, 18.0, 21.7 and 27.4 degrees two theta ± 0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in Figure 5; and combinations thereof. 
Kristalinična sukcinatna sol desfesoterodina prema zahtjevu 6, gdje je kristaliničmi oblik desfesoterodin sukcinata, označenog kao Oblik S1, naznačen podacima izabranima između jednog ili više od sljedećeg: obrazac rendgenske difrakcije praha ima pikove na 7.4, 16.8, 18.0, 21.7 i 27.4 stupnja dva theta + 0.2 stupnja dva theta; obrazac rendgenske difrakcije praha u biti je kakav je prikazan na Slici 5; i njihove kombinacije.
The method according to claim 5, wherein cellular aging is due to exposure to the sun in the skin. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što je stanično starenje posljedica izlaganja kože suncu.
The system of claim 1, wherein the ablation probe (120) is further adapted and configured to be advanced through the urethral wall and into an apex of the prostate lobe. 
Sustav prema zahtjevu 1, naznačen time da je sonda za ablaciju (120) nadalje podešena i konfigurirana za postavljanje kroz stjenku uretre i u vrh režnja prostate.
Subsequently, 46.6 mg/ml caspofungin diacetate, corresponding to 42 mg/ml of caspofungin base, were added, pH value was determined to be 6.59 and was adjusted with 1 N acetic acid to pH 6.0 or pH 6.5, respectively. 
Farmaceutski sastav prema zahijevu 4, naznačen time, da obuhvaća 42 mg/ml kaspofungina, računajući kao kaspofungin bazu, što odgovara za 46,6 mg/ml kaspofungin diacetata, 50 mg/ml punila za povećanje mase, koje je mješavina 20 mg/ml manitola 1 30 mg/ml saharoze, i vodu.
A method according to claim 1 or 2, wherein in subsequent use of the inhaler the outer side surface of the manifold and the peeling edge (119) are arranged so as to define a gap sufficient to enable the cover sheet (7) to pass therethrough, said gap being less than or equal to about 1 mm, preferably less than or equal to about 0.8 mm, more preferably less than or equal to about 0.4 mm. 
Inhalator u skladu s patentnim zahtjevom 1 ili 2, pri čemu su, kada je u uporabi, vanjska postranična površina cjevovoda i rub za odvajanje (119) postavljeni tako da određuju procjep dovoljan za omogućavanje prolaska pokrovnoj ploči (7), navedeni procjep je manji od ili jednak približno 1 mm, poželjno manji ili jednak približno 0.8 mm, još poželjnije manji ili jednak približno 0.4 mm.
In the curing process, said hotmelts change from a thermoplastic to a thermosetting state. 
U postupku lijepljenja, navedene vruće otopine se mijenjaju iz termoplastičnog stanja u termo-stabilno stanje.
is a non aromatic heterocycle the term "non aromatic heterocycle" denotes a five or six membered heterocyclic ring, containing one or two heteroatoms, selected from the group consisting of O, N or S or is OR' or N(R")2; 
R* je nearomatski heterocikl, termin "nearomatski heterocikl" označava heterociklički prsten s pet ili šest članova koji sadrži jedan ili dva heteroatoma, izabranih iz skupine koja se sastoji od O, Nili Silije OR' ili N(R"),;
A solid composition according to claim 1, comprising shea butter in an amount of from about 5% to about 94% by weight of the total composition. A solid composition according to claim 8, comprising shea butter in an amount of from about 15% to about 35% by weight of the total composition. 
Ne-jestivi kruti kozmetički pripravak prema bilo kojem od zahtjeva 1 do 6, naznačen time da sadrži shea maslac u količini od 5% do 94 masenih% ukupnog pripravka, poželjno u količini od 15% do 35 masenih% ukupnog pripravka.
A device as claimed in any preceding claim, wherein the proximal hoop has proximal peaks and distal peaks (205, 206) and the filter elements (207) are connected to the support at or adjacent said distal peaks of the proximal hoop. 
Vaskularni uređaj za filtriranje prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što proksimalni obruč sadrži dvije krune s proksimalnim i distalnim vrhovima, te pri čemu su filtarski elementi (874) povezani s navedenim distalnim vrhovima (871).
The method according to claim 1 or 2, wherein the first number of aggregated control channel elements is 1 or 2 and the second number of aggregated control channel elements is 4 or 8. 
Metoda prijema sukladno jednom od zahtjeva od 1 do 3, naznačena time da je prva vrijednost razine agregacije 2 i da je druga vrijednost razine agregacije 4 ili 8.
A plant having reduced expression or activity of a DA2 polypeptide comprising a RING domain of SEQ ID NO: 2 and reduced expression or activity of a DA1 polypeptide or a DA1 and an EOD1 polypeptide, wherein the expression or activity of one or more of said DA2, DA1 and EOD1 polypeptides is reduced by the incorporation of a heterologous nucleic acid into one or more cells of the plant, wherein the heterologous nucleic acid expresses a suppressor nucleic acid which reduces expression of the one or more polypeptides, and wherein the plant has an increased mass of seeds per unit area, growth and/or biomass relative to wild-type. 
Biljka koja ima smanjenu ekspresiju 1li aktivnost polipeptida DA2 koji obuhvaća RING-domenu od SEQ ID NO: 2 i smanjenu ekspresiju ili aktivnost polipeptida DA1 ili oba polipeptida DA1 i EODI, naznačena time, da je ekspresija ili aktivnost jednog ili više polipeptida DA1, DA2 1 EODI smanjena pomoću ugradnje heterologne nukleinske kiseline u jednu ili više stanica biljke, gdje heterologna nukleinska kiselina eksprimira supresorsku nukleinsku kiselinu koja smanjuje ekspresiju jednog ili više polipeptida, 1 pritom biljka ima povećanu količinu sjemena po jediničnoj površini, povećani prirast i/ili povećanu biomasu, u odnosu na divlju vrstu biljke.
water, and having a viscosity in the range of 200 to 2000 mPa·s, measured with a Brookfield RVDV-II Viscometer at 25 °C. 
voda, i viskoziteta u rasponu od 200 do 2000 mPa x s, mjereno pomoću Brookfield RVDV-II viskozimetar na 25 °C.
A compound of Formula VII: wherein 
Spoj Formule VII:
A process to make fusidic acid cream as claimed in claim 1, wherein said cream base comprises a preservative, an acid, a co-solvent, an emulsifier and a waxy material along with water, preferably purified water. 
Postupak za proizvodnju kreme s fusidinskom kiselinom prema patentnom zahtjevu 1, naznačen time, da navedena baza kreme sadrži konzervans, kiselinu, ko-otapalo, emulgator te voštanu tvar, zajedno s vodom, prvenstveno pročišćenom vodom.
A process for preparing a compound according to claim 19, which comprises: 
Postupak za dobivanje spoja prema zahtjevu 19, naznačen time da sadrži: reakciju spoja prema formuli (V),
Preparation of the solvent: 
Broj objave europskog patenta:
The antibody or antigen binding fragment thereof, or the antibody drug conjugate for use of claim 11 or 12, wherein the cancer is bladder cancer, breast cancer, pancreatic cancer, lung cancer, ovarian cancer, esophageal cancer, or head and neck cancer. 
Konjugat antitijela 1 lijeka za uporabu prema patentnom zahtjevu 19, gdje je rak rak gušterače, rak pluća, rak mjehura, rak kolona, rak jajnika, rak jednjaka, rak glave i vrata, ili rak dojke.
Use of a compound according to any one of claims 1 to 47 in the manufacture of a medicament for the treatment of type II diabetes. A compound according to any one of claims 1 to 47 for use in a method of treatment to decrease food intake in an individual. 
Uporaba pripravka u skladu s bilo kojim zahtjevom 1 do 31, 33, 35, 37, 40, 42, 45 i 47, naznačena time, da so koristi u izradi lijeka za liječenje dijabetesa tip II.
The TNFR1 antagonist of claims 3-5 for use in medicine, wherein it is administered Orally, via the GI tract, or via pulmonary delivery. 
Antagonist TNFRI1 u skladu s patentnim zahtjevima 3-5 namijenjen upotrebi u medicini, naznačen time što se primjenjuje oralno, putem GI sustava, ili unosom preko pluća.
The process of claim 7, wherein the amount of citrate ion source, pyrophosphate ion source, and ferric ion source each contain less than 250 micrograms of the metals aluminum, antimony, arsenic, bismuth, cadmium, copper, lead, mercury, molybdenum, thallium, and tin per gram of the ion source. 
Postupak prema zahtjevu 7, gdje količina izvora iona citrata, izvora iona pirofosfata 1 izvora feri iona svaka sadrži manje od 250 mikrograma metala aluminija, antimona, arsena, bizmuta, kadmija, bakra, olova, žive, molibdena, talija 1 kositra po gramu izvora iona.
A composition according to claim 10, which is an aqueous solution and comprises from 1 to 112 mg/ml of granisetron hydrochloride and 2 to 10 mg/ml of chitosan glutamate. 
Kompozicija prema zahtjevu 10, koja je vodena otopina i sadrži od 1 do 112 mg/ml granisetron hidroklorida i 2 do 10 mg/ml hitosan glutamata.
The method of paragraph 21, wherein the parasite is a nematode, a cestode, a trematode or a filarial parasite. 
Mekani veterinarski pripravak za žvakanje za uporabu prema zahtjevu 33, naznačen time, da se kod parazita radi o nematodu, cestodu, trematodu ili filarijalnom parazitu.
In the case of gene therapy another object of the invention is the use of the nucleotide sequences coding for the antigens of the invention as medicaments, in particular for the preparation of medicaments useful for the treatment and prevention of Toxoplasma gondii infections. 
Uporaba himernih antigena iz nekog od zahtjeva 1 do 4 ili 11, naznačena time, što se upotrebljavaju kao aktivni sastojci za pripremanje lijekova za prevenciju ili liječenje infekcija Toxoplasma-om gondii, .
The composition of embodiment 4, wherein the common carrier is H.influenzae protein D. 
Sastav prema zahtjevu 4, naznačen time da je zajednički nosač Hinfluenzae protein D.
Because the inspiratory air stream in multi-dose devices is often straight across the dose measuring cavity, and because the massive and rigid dose measuring systems of multi dose inhalers can not be agitated by this inspiratory air stream, the powder mass is simply entrained from the cavity and little de-agglomeration is obtained during discharge. 
Kako struja usisanog zraka u napravama za više različitih doza često prolazi ravno iznad šupljine za odmjeravanje doza, a budući se masivni i čvrsti sustavi za odmjeravanje doza u inhalatori ma za više različitih doza ne mogu pomicati uslijed prolaska struje usisnog zraka, praškasta se masa jednostavno odnosi 1z šupljine, a tijekom pražnjenja dolazi do manjeg raspršivanja.